Acino ? Delivering Health

More documents

Recommendations

Info

Extended release parenterals Biodegradable subcutaneous implants Drug implants are monolithic rods (length of 1-2 cm and a diameter of 1-2 mm) containing the active ingredient embedded into a biodegradable polymer matrix (poly-lactide-co-glycolide) as a carrier substance. Physicians apply them with a commercially available standard syringe under the skin (subcutaneous). Technologies Melt extrusion (monolithic implants) Dosage forms Biodegradable subcutaneous drug implants 18
Extended release parenterals Advantages of drug implants Continuous and steady drug release over a defined time period (1 to 6 months) Patient continuously medicated as prescribed Monthly, quarterly or half-yearly application (long dosing intervals, even exceeding those patches) With regard to comfort, patient compliance and continuous release of the active ingredient, subcutaneous biodegradable implants offer similar advantages as transdermal therapeutic systems 19
Page 1 and 2: Acino - Delivering Health Investor
Page 3 and 4: Acino - drug delivery specialist, m
Page 5 and 6: Acino’s growth drivers Fully expl
Page 7 and 8: Technology platform Oral modified r
Page 9 and 10: Oral modified release forms MUPS (M
Page 11 and 12: Technology platform Oral dispersibl
Page 13 and 14: Technology platform Transdermal sys
Page 15 and 16: Transdermal systems Why transdermal
Page 17: Technology platform Extended releas
Page 21 and 22: Development projects Ferrous sulfat
Page 23 and 24: Development projects Rivastigmine T
Page 25 and 26: Development projects Goserelin & le
Page 27 and 28: Development projects Goserelin 1 &
Page 29 and 30: Development projects Leuprorelin 1
Page 31 and 32: Acino’s development pipeline Stat
Page 33 and 34: Acino - Delivering Health Thank you
Page 35 and 36: Entering emerging markets / “Swis
Page 37 and 38: Acino Switzerland 2009 BtC markets
Page 43 and 44: Opportunities Products with added v
Page 45 and 46: Acino Switzerland: Product Portfoli
Page 47 and 48: Acino portfolio Roll-out in new ter
Page 49 and 50: Criteria for selecting products for
Page 51 and 52: Acino’s business model (example)
Page 53 and 54: Optimized BtB Concept - Geographica
Page 55 and 56: Technical Marketing and Operations:
Page 57 and 58: Acino’s production importance Tec
Page 59 and 60: Production Technologies: Value for
Page 61 and 62: Pellets Innovative technologies for
Page 63 and 64: Pellet Projects High volume project
Page 65 and 66: Granulates Hot melt granulation Sp
Page 67 and 68: Manufacturing Process 67
Page 70 and 71:
Implants Implant manufacturing capa
Page 72 and 73:
Opportunity: High Quality Service S
Page 74 and 75:
Summary Focus on niche technologies
Page 76 and 77:
Competitive advantage factor: HighT
Page 78 and 79:
Micro Error Tracking System (METS)
Page 80 and 81:
Strategy to cope with declining mar
Page 82 and 83:
Financials Robert Schmid, Head of I
Page 84 and 85:
Promising potential areas of synerg
Page 86 and 87:
Reduced currency exposure Mepha / C
Page 88 and 89:
Summary and strategy Peter Burema,
Page 90 and 91:
Acino’s growth drivers Fully expl
Page 92 and 93:
Geographic break-down of revenue DE
Page 94:
Acino - Delivering Health Thank you
show all

Acino ? Delivering Health

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?